Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hospitalized Adult Patients Clear all
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

NCT02927431
View directory record Official record
Conditions
Virus Diseases
Interventions
Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Sep 7, 2026, 10:26 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease

NCT02076438
View directory record Official record
Conditions
Diarrhea
Interventions
Probiotics
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

NCT04738123
View directory record Official record
Conditions
Schizophrenia, Schizophrenia; Psychosis
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 7, 2026, 10:26 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140
View directory record Official record
Conditions
COVID-19 SARS-CoV-2 Infection
Interventions
ibuzatrelvir, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
2,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
86
States / cities
Little Rock, Arkansas • Bakersfield, California • Huntington Park, California + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 7, 2026, 10:26 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

NCT04369469
View directory record Official record
Conditions
COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
Interventions
Ravulizumab, BSC
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

NCT03315104
View directory record Official record
Conditions
Influenza A H3N2, Influenza A H1N1
Interventions
FLU-IGIV, Placebo for FLU-IGIV
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Not applicable Interventional

Patient-Centered Tablets: Applications for Inpatient Admissions

NCT02109601
View directory record Official record
Conditions
Mobile Health
Interventions
Extensive bedside training for accessing patient portal, Limited bedside training on patient portal use.
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19

NCT04425252
View directory record Official record
Conditions
COVID-19
Interventions
Brequinar, Standard of Care
Drug · Other
Lead sponsor
Clear Creek Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Hartford, Connecticut • Jacksonville, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

NCT01432444
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole (Abilify®) IM Depot Injection
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
119
States / cities
Dothan, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 97 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 7, 2026, 10:26 PM EDT
Terminated Phase 2 Interventional Results available

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

NCT04470622
View directory record Official record
Conditions
COVID-19
Interventions
Aprepitant injectable emulsion, Saline Placebo
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Sheffield, Alabama • Orange, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 7, 2026, 10:26 PM EDT
Terminated Phase 1 Interventional

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

NCT02780583
View directory record Official record
Conditions
Macrophage Activation Syndrome
Interventions
kineret, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 7, 2026, 10:26 PM EDT
Terminated Not applicable Interventional Results available

Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions

NCT01600677
View directory record Official record
Conditions
Medication Adherence, Medication Nonadherence, Adverse Reaction to Drug
Interventions
Computerized medication delivery unit, Usual care
Device · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

NCT04575038
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Brequinar, Placebo
Drug
Lead sponsor
Clear Creek Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 7, 2026, 10:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

NCT05081388
View directory record Official record
Conditions
SARS-CoV-2
Interventions
REGN14256, imdevimab, casirivimab + imdevimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
La Mesa, California • Long Beach, California • Mission Viejo, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 7, 2026, 10:26 PM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Not applicable Interventional Results available

Improving Patient Walking During Hospitalization

NCT04479943
View directory record Official record
Conditions
Early Mobility, Older Adults, Hospital Acquired Condition
Interventions
MOVIN, Surveys and Focus groups
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
65 Years and older
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 7, 2026, 10:26 PM EDT
Recruiting Not applicable Interventional

Animal Assisted Therapy

NCT07227181
View directory record Official record
Conditions
Anxiety, Trauma, Hospitalized Adult Patients, Rehabilitation, Physical Mobility Impairment, Therapy Dog, Pediatric Patient (1m-21y)
Interventions
Therapy Dog, Standard mobilization
Other
Lead sponsor
Andrew Bernard
Other
Eligibility
4 Years to 99 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 7, 2026, 10:26 PM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19

NCT04771351
View directory record Official record
Conditions
Covid19
Interventions
COVI-AMG, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Brandon, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Phase 2 Interventional

A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections

NCT00303589
View directory record Official record
Conditions
Soft Tissue Infections
Interventions
Standard care, beta-lactam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Mobile, Alabama • Melbourne, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Phase 3 Interventional

Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

NCT01605864
View directory record Official record
Conditions
Community Acquired Bacterial Pneumonia
Interventions
Efficacy of ceftaroline
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 7, 2026, 10:26 PM EDT
Completed No phase listed Observational

Feasibility Study of Hematology Parameters in COVID-19 Disease

NCT04816630
View directory record Official record
Conditions
Covid19, Sepsis, Adults, Emergency Department
Interventions
CBC-Diff Monocyte Volume Width Distribution
Device
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

NCT04426695
View directory record Official record
Conditions
COVID-19
Interventions
REGN10933+REGN10987 combination therapy, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
96
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients

NCT00606489
View directory record Official record
Conditions
Burns
Interventions
Caldolor, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Orlando, Florida • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Sep 7, 2026, 10:26 PM EDT
Completed Not applicable Interventional

Time in Glucose Hospital Target

NCT05135676
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Blinded CGM, real-time CGM
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 7, 2026, 10:26 PM EDT